Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.45 |
| ▸ | IL1B | P01584 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4358980 | 0.93 | P2RX7 (0.46) | P2RX7IL1BLMNAMEN1KMT2A | |
| SCHEMBL4540882 | 0.93 | P2RX7 (0.47) | P2RX7IL1B | |
| SCHEMBL4364374 | 0.91 | P2RX7 (0.55) | P2RX7IL1BLMNAMEN1KMT2A | |
| SCHEMBL4542289 | 0.90 | P2RX7 (0.44) | P2RX7IL1BLMNACACNA1GMEN1 | |
| SCHEMBL3689141 | 0.89 | P2RX7 (0.46) | P2RX7IL1B | |
| SCHEMBL3645343 | 0.89 | P2RX7 (0.54) | P2RX7IL1BLMNA | |
| SCHEMBL3645106 | 0.87 | MEN1 (0.44) | P2RX7IL1BLMNACACNA1GMEN1 | |
| SCHEMBL11885564 | 0.87 | P2RX7 (0.46) | P2RX7IL1B | |
| SCHEMBL3745438 | 0.84 | P2RX7 (0.57) | P2RX7IL1B | |
| SCHEMBL4534853 | 0.82 | P2RX7 (0.52) | P2RX7IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190680-A1 | Heteroaryl Amide Analogues | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | claimed |
| WO-2009108551-A2 | HETEROARYL AMIDE ANALOGUES | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | claimed |
| US-20120190680-A1 | Heteroaryl Amide Analogues | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120190680-A1 | Heteroaryl Amide Analogues | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120190680-A1 | Heteroaryl Amide Analogues | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| WO-2009108551-A2 | HETEROARYL AMIDE ANALOGUES | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009023623-A1 | HETEROARYL AMIDE ANALOGUES | H, LUNDBECK A/S (DK) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190680-A1 | Heteroaryl Amide Analogues | P2RX3, P2RX2, ADORA2A | P2RX7 5/4885IL1B 403/4885LMNA 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.